“`html
Recce pharmaceuticals Secures Over A$5 Million in R&D Tax Refund, Fuels Anti-infective Pipeline
Table of Contents
A$5.34 million cash refund from the Australian Taxation Office will accelerate progress of novel treatments for antibiotic-resistant infections.
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has received a significant boost to its research and development efforts with a A$5,339,202 cash refund from the Australian Taxation Office. The refund, stemming from the Research and Development (R&D) Tax Incentive, covers eligible activities undertaken through June 30, 2025, and was received in full.
The company is pioneering a new class of synthetic anti-infectives, addressing the growing global threat of antibiotic resistance. According to a company release, the Australian Federal Government’s 43.5% R&D Tax Incentive applies to qualifying activities conducted worldwide, highlighting the nation’s commitment to fostering innovation in the pharmaceutical sector.
Recce anticipates further non-dilutive funding with an additional R&D Tax Incentive submission already lodged.Pending review and approval by the ATO,the company expects a further cash refund of approximately A$3 million,completing its FY25 R&D rebate. This additional funding will be crucial in supporting ongoing clinical trials and expanding its research programs.
“This substantial rebate will go towards funding our R&D programs, both locally and overseas, including our ongoing Phase 3 Clinical Trial in Indonesia, and further domestic clinical programs,” stated James Graham, CEO of Recce Pharmaceuticals. “The funds received provide further confidence in our objectives and support the continued progression of Recce’s anti-infective portfolio. we appreciate the Australian Government’s ongoing commitment to supporting innovation and R&D, and we look forward to delivering important milestones as we advance our new class of synthetic anti-infectives.”
Addressing the Global Threat of Antibiotic resistance
recce Pharmaceuticals is focused on developing solutions to combat infections caused by increasingly resistant bacteria. The company’s pipeline features three patented, broad-spectrum synthetic polymer candidates: RECCE® 327 (R327), designed as an intravenous and topical treatment for serious Gram-positive and Gram-negative bacterial infections, including those caused by “superbug” strains; RECCE® 435 (R435), an oral therapy for bacterial infections; and RECCE® 529 (R529), currently in development for viral infections.
The company’s approach utilizes multi-layered mechanisms of action, aiming to overcome a key limitation of existing antibiotics – the rapid development of bacterial resistance. This innovative strategy is gaining recognition from leading global health organizations.
Regulatory Progress and Global Recognition
The World Health Organization has included R327, R435, and R529 on its list of antibacterial products in clinical development for priority pathogens, underscoring their potential impact on global health. in the United States, the Food and Drug Administration (FDA) has granted R327 Qualified Infectious Disease Product (QIDP) designation under the GAIN Act, potentially expediting its path to market with Fast Track status and the possibility of 10 years of market exclusivity upon approval.
